LUNG Pulmonx Corporation
CATEGORY BREAKDOWN
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
> 50% strong
Gross Margin
Revenue retained after direct costs
> 50% strong
Cash Runway
Months of cash at current burn rate
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
< 25% strong
Price / Sales
Market cap relative to trailing revenue
< 3x strong
Rule of 40
Growth rate plus operating margin
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
< 5% ideal
5 more metrics available
Unlock all 8 metrics, score history, watchlist, and side-by-side comparison.
Try Free for 30 DaysAI ANALYSIS REPORT
AI-GENERATEDBUSINESS SUMMARY
Pulmonx Corporation (LUNG) is a healthcare company trading on NMS with a market capitalization of $73M. The company currently carries a SOLID rating of 64/100, indicating above-average fundamental quality. The fundamental profile shows moderate revenue growth at 22.0% year-over-year, paired with strong gross margins well above industry average at 74.0%. The balance sheet shows elevated leverage that warrants monitoring, and the company has adequate cash runway of about 2 years.
VERDICT
LUNG scores 64/100 — a solid fundamental profile with room for improvement in select areas. This report is based on the latest available financial data and is intended as a starting point for research, not a buy or sell recommendation.
MARKET OPPORTUNITY
In the healthcare sector, cash runway and pipeline progress are critical metrics. Revenue quality depends on whether income comes from product sales, partnerships, or milestones. Pulmonx Corporation operates with meaningful insider ownership of 10.8%, which provides a signal about management's confidence in the company's direction. At a market cap of $73M, the company is deeply discounted on a price-to-sales basis (under 1x) at 0.8x P/S. The combination of these factors positions LUNG as a potentially interesting opportunity for investors seeking fundamental quality in the small-cap space.
REVENUE QUALITY
Revenue growth stands at 22.0% year-over-year, which is above the typical small-cap growth rate. Gross margins of 74.0% are strong and suggest pricing power or an asset-light business model. The Rule of 40 score of -47 is well below the benchmark, indicating challenges in both growth and profitability. Cash runway of 27 months provides a comfortable buffer for executing on growth plans.
COMPETITIVE ADVANTAGE
Evaluating Pulmonx Corporation's competitive position requires looking beyond the numbers. Insider ownership at 10.8% is relatively low, which may indicate that management's interests are less aligned with shareholders. The high gross margins suggest some form of competitive moat — whether through proprietary technology, brand value, regulatory barriers, or network effects. Share count management has been reasonable. Investors should research the specific sources of competitive advantage — patents, customer switching costs, scale economies, or brand — that could protect margins over time.
GROWTH THESIS
LUNG presents a reasonable fundamental case at current levels. The low 0.8x P/S ratio could represent value if the company can stabilize or accelerate its growth. Key catalysts to watch include: revenue growth trajectory over the next 2-3 quarters, margin expansion or contraction, and any changes in insider buying or selling activity.
KEY RISKS
Execution risk is significant — many small-cap companies in this sector fail to transition from growth to profitability. The elevated debt-to-equity ratio of 66x increases financial risk and limits the company's flexibility to weather downturns or invest in growth. As a micro-cap stock, liquidity risk is a factor — wider bid-ask spreads and lower trading volumes can amplify price moves. Small-cap stocks carry inherently higher risk than large-caps, including limited analyst coverage, lower institutional ownership, and higher sensitivity to market downturns. Always conduct thorough due diligence beyond quantitative metrics.
Full AI Report available
Unlock the complete analysis including market opportunity, revenue quality, competitive moat, growth thesis, and risk assessment.
Try Free for 30 DaysReport generated: Mar 26, 2026
SCORE HISTORY
Track how this score changes over time. Start your free trial to see the full score trend chart.
RELATED STOCKS
SCORE ALERT
Get notified when LUNG's score changes by 5+ points.
DATA INFO
Last updated: Mar 11, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.